The HCPLive Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...
April 26th 2024
A meta-analysis of 12 trials suggests catheter ablation for atrial fibrillation reduces heart failure events in HFrEF patients but not in HFpEF.
Medical Crossfire®: Updates in Continuous Glucose Monitoring—Having the Important Conversations With Your Patients
View More
Evaluating the Recent Advancements in Chronic Kidney Disease Treatment: A Case-Based Approach to Managing CKD and Related Comorbidities
View More
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
7th Annual New York Cardio-Endo-Renal Collaborative (NY CERC)
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
Advances in Treatment Options for Chronic Pain
Chronic pain is a difficult condition to diagnose and manage, especially since most diagnostic measures are subjective and treatment varies from patient to patient. A key to diagnosing and treating chronic pain is to have a strong understanding of the different diagnostic tools and treatment options available.
Omega-3 Therapy Vascepa Reduces Triglycerides in Severe Hypertriglyceridemia Patients
As an adjunct to diet and exercise, Amarin's lipid-regulating agent Vascepa (icosapent ethyl capsules) is indicated to reduce triglyceride levels in adult patients with severe hypertriglyceridemia, or very high triglyceride (TG) levels greater than or equal to 500 milligrams per deciliter (mg/dL).
Blood Thinner Brilinta Treats Acute Coronary Syndrome
Approved by the FDA in July 2011, AstraZeneca's Brilinta (ticagrelor tablets) is a twice-daily treatment to reduce the rate of myocardial infarction and cardiovascular death in adult patients with acute coronary syndrome.
VIDEO: Many Heart Failure Patients Cannot Tolerate Recommended Doses of Beta Blockers
March 11th 2013Jeffrey S. Borer, MD, of the Howard Gilman Institute for Heart Valve Disease, discusses treating patients with heart failure with beta-blockers and whether there are any patients in this group who are not good candidates for this treatment.
Modern Technology Reveals Atherosclerosis Was Prevalent in Ancient Populations
March 11th 2013Investigators in the expanded HORUS trial using CT scans of ancient mummies from multiple populations and geographic regions report finding evidence of probable or definite atherosclerosis in nearly one-third of samples.